PRCT Stock Chart & Stats
$357.00
$0.00(0.00%)
At close: 4:00 PM EDT
$357.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$305.01 - $1,217.38
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$20.66B
Enterprise Value$1.14K
Total Cash (Recent Filing)$227.91M
Total Debt (Recent Filing)$77.50M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Oct 29, 2026EPS Estimate
-6.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding57,273,660
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$390.80Price Target Upside9.47% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-28.22
Revenue Forecast (FY)$6.68B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Procedure GrowthRapid revenue and procedure growth indicates expanding clinical adoption and a widening commercial footprint. Continued volume expansion should support greater recurring handpiece revenue, improve utilization of the installed base, and provide operating leverage as the business scales.
Improving Gross Margins And Pricing PowerHigh and improving gross margins, alongside record HYDROS pricing, suggest meaningful product value and customer acceptance. This combination can strengthen contribution from each system placement and consumable procedure, supporting a more durable path toward profitability as volumes rise.
Clinical Evidence And Regulatory SupportA substantial clinical evidence base and continued progress in randomized studies can reinforce physician confidence, support guideline adoption, and expand the addressable treatment opportunity. FDA study authorization also provides a structured route to generate evidence for future commercial development.
Bears Say
Persistent Operating And Net LossesThe company remains materially unprofitable despite strong sales growth, showing that commercial expansion has not yet covered its operating cost base. If losses persist, internal funding for growth will remain limited and management may face pressure to reduce investment or seek additional capital.
Worsening Negative Cash GenerationIncreasing cash burn is a durable execution concern because scaling the installed base currently consumes substantial liquidity. Although cash and restricted cash totaled $231M, continued negative free cash flow could reduce flexibility and increase financing risk if the profitability transition is delayed.
Legacy AQUABEAM Utilization WeaknessWeak utilization across legacy AQUABEAM accounts creates a risk to recurring procedure and consumables revenue while the installed base transitions toward HYDROS. The uncertainty around the causes and recovery of this softness makes near-term growth execution more dependent on new placements and upgrades.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $305.01 and its highest was $1217.38 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $20.66B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Oct 29, 2026 which is in 49 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Aug 04, 2026. The company reported -$8 earnings per share for the quarter, missing the consensus estimate of -$7.864 by -$0.136.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -6.62.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 57,273,660 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$8 in its last earnings report, missing expectations of -$7.864. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in MX:PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$390.80 (9.47% Upside)
$390.80 (9.47% Upside)
Blogger Sentiment
Bullish
MX:PRCT Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $8.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive outlook driven by strong HYDROS adoption, record pricing, solid top-line growth (Q2 revenue +19% and procedures +21% YoY), important clinical and regulatory milestones, and a clear path to positive adjusted EBITDA in Q4 2026. Offsetting risks include a concentrated procedure shortfall in legacy AQUABEAM accounts, higher operating expenses that widened losses in the quarter, and some one-time benefits (tariff recovery) supporting margins. Management is focused on upgrades, scaling launch teams, and patient-activation initiatives to drive durable utilization improvements.View all MX:PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$390.80
▲(9.47% Upside)